Skip to main content

Table 1 Demographic criteria of the patients

From: Multi-drug resistance 1 genetic polymorphism and prediction of chemotherapy response in Hodgkin's Lymphoma

Variable

Patients with Complete Remission (CR) N (%)

Patients with Relapsed Disease (RD) N (%)

Number

96

34

Age at diagnosis

  

Median

31

27.5

15-20

16 (16.7)

17 (50)

21-30

32 (33.3)

5 (14.7)

31-40

18 (18.8)

5 (14.7)

> 40

30 (31.2)

8 (20.6)

Gender

  

Males

50 (52.1)

21 (61.8)

Females

46 (47.9)

13 (38.2)

Stage

  

Early stages (I &II)

41 (42.7)

20 (58.8)

Advanced stages (III & IV)

38 (39.6)

12 (35.3)

Missed data

17 (17.7)

2 (5.9)

Presence of B symptoms

  

Yes

54 (56.3)

19 (55.9)

No

31 (32.3)

13 (38.2)

Missed data

11 (11.4)

2 (5.9)

Bone marrow involvement

  

Yes

5 (5.2)

4 (11.8)

No

91 (94.8)

30 (88.2)

Histology

  

Nodular sclerosis

46 (47.9)

16 (47.1)

Mixed cellularity

25 (26)

6 (17.6)

Lymphocyte rich

5 (5.2)

3 (8.8)

Lymphocyte depleted

4 (4.2)

0 (0)

Nodular lymphocyte predominance

1 (1)

5 (14.7)

Classical

7 (7.3)

4 (11.8)

Missed data

8 (8.3)

-

Chemotherapy regimen

ABVD: All the patients

ABVD: Initially all the patients at relapse: ICEa (8), ESHAPb (8), COPPc (3), ABVDd (8), Others: (7).

Number of ABVD cycles

  

< 6 cycles

10 (10.4)

6 (17.6)

6 cycles

77 (80.2)

22 (64.7)

> 6 cycles

9 (9.4)

5 (14.7)

  1. aAdriamycin, Bleomycin, Vinblastine, Decarbazine; bIfosfamide, Carboplatin, Etoposide; cEtoposide, Cisplatin, Cytarabine, Methylprednisolone; dCyclophosphamide, Vincristine, Prednisolone, Procarbazine.